Commentary on ‘Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTS trial’

Alessandro Rossi; Nicola Brunetti-Pierri

doi:10.1002/ctd2.70038

Clinical and Translational Discovery ›› 2025, Vol. 5 ›› Issue (2) : e70038 DOI: 10.1002/ctd2.70038

COMMENTARY

Commentary on ‘Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTS trial’

Alessandro Rossi ¹
, Nicola Brunetti-Pierri ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Alessandro Rossi, Nicola Brunetti-Pierri. Commentary on ‘Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTS trial’. Clinical and Translational Discovery, 2025, 5(2): e70038 DOI:10.1002/ctd2.70038

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	WaldekS, PatelMR, BanikazemiM, Lemay R, LeeP. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790-796.

[2]	MehtaA, ClarkeJT, GiuglianiR, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS—Fabry Outcome Survey. J Med Genet. 2009;46(8):548-552.

[3]	RamaswamiU, BeckM, HughesD, et al. Cardio-Renal Outcomes with long-term agalsidase Alfa enzyme replacement therapy: a 10-year Fabry outcome survey (FOS) analysis. Drug Des Devel Ther. 2019;13:3705-3715.

[4]	GermainDP, HughesDA, NichollsK, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545-555.

[5]	ConsiglieriG, Bernardo ME, Brunetti-PierriN, AiutiA. Ex vivo and in vivo gene therapy for mucopolysaccharidoses: state of the art. Hematol Oncol Clin North Am. 2022;36(4):865-878.

[6]	KhanA, BarberDL, HuangJ, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021;12(1):1178.

[7]	SalehAH, RotheM, BarberDL, et al. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Mol Ther Methods Clin Dev. 2023;28:262-271.

[8]	KhanA, BarberDL, McKillopW, et al. Lentivirus-mediated gene therapy for Fabry disease:5-year end-of-study results from the Canadian FACTS trial. Clin Transl Med. 2025 Jan; 15(1):e70073.

[9]	RossiA, Malvagia S, la MarcaG, ParentiG, Brunetti-Pierri N. Biomarkers for gene therapy clinical trials of lysosomal storage disorders. Mol Ther. 2024;32(9):2930-2938.

[10]	BichetDG, AertsJM, Auray-BlaisC, et al. Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021;23(1):192-201.

[11]	RombachSM, SmidBE, BouwmanMG, Linthorst GE, DijkgraafMG, HollakCE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.

[12]	NajafianB, TondelC, SvarstadE, Gubler MC, OliveiraJP, MauerM. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31(4):865-875.

[13]	MauhinW, LidoveO, MasatE, et al. Innate and adaptive immune response in Fabry disease. JIMD Rep. 2015;22:1-10.

[14]	EichlerF, DuncanC, MusolinoPL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630-1638.

[15]	DuncanCN, Bledsoe JR, GrzywaczB, et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391(14):1287-1301.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.